Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)

NCT01724879 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Philadelphia Positive Acute Lymphoblastic Leukemia

Interventions

DRUG: Dasatinib

Sponsor

Goethe University